⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27949859 | 0.69 | — | — | |
| SCHEMBL11150983 | 0.63 | — | — | |
| SCHEMBL12294410 | 0.63 | — | — | |
| SCHEMBL14013717 | 0.63 | — | — | |
| SCHEMBL2662531 | 0.62 | — | — | |
| SCHEMBL7570470 | 0.62 | — | — | |
| SCHEMBL3691786 | 0.62 | — | — | |
| SCHEMBL3642541 | 0.62 | — | — | |
| SCHEMBL21370470 | 0.61 | — | — | |
| SCHEMBL27633351 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2023-09-28 | — | — | US | claimed |
| WO-2021150918-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2021-07-29 | — | — | WO | claimed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | claimed |
| EP-3765082-A1 | USES, COMPOSITIONS AND METHODS | Fisahn, André (SE) | 2021-01-20 | — | — | EP | claimed |
| WO-2019175395-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2019-09-19 | — | — | WO | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4282862-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-29 | — | — | EP | disclosed |
| US-20230329236-A1 | HERBICIDAL PYRIMIDINE DERIVATIVES | MOA Technology Limited (GB) | 2023-10-19 | — | — | US | disclosed |
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2023-09-28 | — | — | US | disclosed |
| US-20230286963-A1 | CHROMENONE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC CORPORATION | 2023-09-14 | — | — | US | disclosed |
| EP-1483270-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074532-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2001068647-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| US-4585472-A | PRE- AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |